3 results
To compare the efficacy of two dose levels of erlotinib (150 mg and 300 mg) on progression-free survival (PFS) in current smokers with stage IIIB/IV NSCLC after failure of first-line platinum-based chemotherapy.
This study will be conducted to determine the overall hr-HPV agreement between self-sampled cervicovaginal smear (Evalyn Brush) and physician-obtained samples taken by a trained physician (liquid based cervical smear) in a screening population. The…
In this study we want to determine the activity and safety of concurrent interruption of the MAPK and PI3K pathways by the EGFR tyrosine kinase inhibitor erlotinb and metformin, combined with gemcitabine in patients with metatastatic pancreatic…